Effect of artemether on rat hepatocytes during acute damage by Oguntibeju, OO et al.
African Journal of Biotechnology Vol. 10(61), pp. 13238-13243, 10 October, 2011     
Available online at http://www.academicjournals.org/AJB 
DOI: 10.5897/AJB11.716 




Full Length Research Paper 
 
Effect of artemether on rat hepatocytes during acute 
damage 
 
Oguntibeju, O. O.1*, Akinola, F. F.2 and Okonkwo, K. G.3 
 
1
Department of Biomedical Sciences, Faculty of Health and Wellness Sciences, Cape Peninsula University of 
Technology, South Africa. 
2
Department of Physiology, Ladoke Akintola University of Technology, Ogbomoso, Oyo State, Nigeria. 
3
Department of Biomedical Sciences, Ladoke Akintola University of Technology, Ogbomoso, Oyo State, Nigeria. 
 
Accepted 24 August, 2011 
 
The aim of this study was to investigate the hepatocellular regeneration ability of artemether in 
experimental CCl4-induced acute damage in rat hepatocytes. 20 Wistar rats were equally allocated to 4 
groups. The first group was designated as the distilled water control group (group 1); the second group 
was CCl4 toxic control (group 2) and received oral administration of CCl4 (50 mg/kg body weight diluted 
1:1 in Tween 80) for three days. The third group (group 3) was treated with CCl4 followed by a 
subsequent administration of artemether and the fourth group (group 4) received artemether (50 mg/kg 
body weight) for 3 days. The body weight was recorded before and after the experiment and the plasma 
aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkanine phosphatase (ALP) and 
album (ALB) levels were determined as markers of hepatocellular damage. Plasma AST and ALT levels 
were significantly higher in group 2, in comparison with group 1 (P < 0.05). Also, increase in ALP was 
observed in group 2 when compared to group 1. Observed improvement in plasma AST, ALT and ALP 
was recorded in group 3. In conclusion, artemether may have a possible regenerating effect on 
hepatocellular damage as it showed inhibitory effect of CCl4 and could thus enhance normal liver 
functions. 
 





Artemether is a semi-synthetic drug used to treat malaria, 
especially chloroquine resistant malaria in Nigeria. 
Malaria has continued to be a major health problem in 
some parts of the world, especially in tropical countries 
(WHO, 2003). In sub-Saharan Africa, over a million 
persons die annually from malaria infection. This infection 
is caused by protozoan in the genus plasmodium which is 
transmitted by female anopheles mosquitoes. The 
plasmodium species that infect humans are Plasmodium 
falciparum, Plasmodium malariae, Plasmodium vivax and 
Plasmodium ovale. Characteristically, the infection 
causes recurring attacks of severe chills, high fever and 
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2005). Delay in treating malaria may result in rapid 
deterioration in the patients' conditions, together with the 
development of a number of life threatening compli-
cations. One of such complications includes acute liver 
damage especially due to P. falciparum (Ayyub et al., 
2000). 
Consequently, chemotherapy is initiated as using 
antimalarial drugs. Chloroquine and quinine have been 
generally used as antimalarial drugs (Lehne et al., 1990; 
Falade et al., 2005). They are active against erythrocytic 
phases of the parasites, sporozoites and the exo-
erythrocytic phases. However, the chloroquine resistant 
strains of the malaria parasites are much more prevalent 
in tropical countries such as Nigeria. WHO reported that 
chloroquine resistance is now virtually global and 
recommended as an effective treatment for patients with 
uncomplicated or severe malaria using quinine or where 






Artemisinins are derived from leaves of a plant called 
sweet wormwood or sweet annie (Artemisia annua) by 
Chinese scientists. Artemisinins” extracts have antipyretic 
properties. Since this initial discovery, a wide range of 
semi-synthetic, oil and water soluble derivatives of 
artemisinin have been developed with variety of formu-
lations (Meshnick et al., 2002). Artemisinin derivatives 
have impressive parasiticidal properties in vivo and in 
vitro (White, 1997; Haynes et al., 2003). It rapidly arrest 
parasite metabolism and kill parasites more quickly than 
other antimalaria drugs (White, 1994).  
Prospective clinical studies of over 10,000 patients, 
including post marketing surveillance of 4,600 patients in 
Thailand, have shown that this class of drugs reduces 
parasitemia and malaria-related symptoms more prom-
ptly than any previously known antimalarial agent and 
without drug-related adverse effects (WHO, 1998). Oral, 
rectal and intra-muscular regimens are generally rapidly 
effective and well tolerated treatments for both severe 
and uncomplicated falciparum malaria (Murphy et al., 
1997). As a fast-acting antimalarial agent, artemether 
starts acting within 12 h of administration and makes it 
very useful in managing severe and complicated P. 
falciparum malaria and also effective in treating 
chloroquine-resistant strains of P. falciparum (Murphy et 
al., 1997; Falade et al., 2005). 
Cases of hepatic dysfunction are being increasingly 
reported in patients with P. falciparum infection, from 
different parts of the world. The extent of hepatocellular 
dysfunction varies from mild abnormalities in liver 
function tests to hepatic failure. Patients with hepato-
cellular dysfunction in malaria are more prone to develop 
complications, but have a favorable outcome if hepatic 
involvement is recognized early, reversed and managed 
properly (John, 1995).  
However, it is important to examine for hepatic 
dysfunction in patients with severe malaria, distinguish it 
from fulminant hepatic failure and manage it aggressively 
and this has increased the importance of the design and 
discovery of antimalarial drugs that will also confer 
significant protective and regenerative effect on the liver 
(John, 1995). 
A study of such significant regenerative effect will be 
possible by exploring the fact that there is increase in 
hepatic enzymes activities indicated to be liver damage 
which has been observed in carbon tetrachloride induced 
liver damage using apparently healthy rats as experi-
mental model (John, 1995). 
Previous work has been done on artemether in areas 
such as potency and hepatotoxicity. However, conside-
ring the fact that it is one of the most active antimalarial 
drug recommended by World Health Organization in 
cases of uncomplicated malaria, especially in P. 
falciparum infection, this study is serves as a post-market 
non-clinical study of the drug in Nigeria and is intended to 
explore the possibilities that this novel antimalarial drug 
could  have  regenerative  effect  on  acute  liver  damage  




which are associated with severe falciparum malaria 
which is common in Nigeria. The study aimed to 
investigate the possible hepatic regenerative effect of 
artemether on carbon tetrachloride induced acute liver 
damage and its significance using a rat model. 
 
 




This was an experimental laboratory-based study. 
 
 
Animal care  
 
The experiment was carried out at the Animal House, Department 
of Biomedical Science, Faculty of Basic Medical Science, College of 
Health Sciences, Ladoke Akintola University of Technology, 
Osogbo, Nigeria and the study lasted for a period of 3 weeks. 
Twenty (20) Wistar rats weighing 120 to 220 g each were acquired 
from the animal house of the University. They were housed in 
cages and kept in the Animal House of the Department of 
Biomedical Science, Osogbo with an average ambient temperature 
of 28 to 32°C with a 12 h light-dark cycle and received rat feed (rat 
pellet) and water ad libitium during an acclimatization period of two 
weeks and also throughout the period of the experiment. The 




Experimental design and protocol 
 
20 Wistar rats were weighed and divided into four (4) groups of 5 
(five) animals in each group as follows: Group 1: Untreated control: 
fed with standard rat pellet and water only throughout the period of 
experimentation. Group 2 (positive control): treated with carbon 
tetrachloride (diluted 1:1 in Tween 80) with a dose of 50 mg/kg 
body weight orally, once daily for 3 days to induce acute liver 
damage. Group 3 (test): Liver damage induced rats treated with 
artemether solution orally with dose of 50 mg/kg body weight, once 
daily for 3 days. Group 4 (drug control): Treated with artemether 
with an oral dose of 50 mg/kg body weight dissolved in Tween 80, 





At the end of the experiment, blood samples (2 ml) were collected 
from each rat by tail bleeding and subsequent cardiac puncture 
using 2 ml syringes, into separate lithium heparinized containers. 
The plasma was extracted from each sample by centrifugation at 
4000 rpm for 10 min. Plasma was stored at -20°C. The effect of 
carbon tetrachloride and artemether and their combined effect were 






Estimation of plasma transaminases 
 
Plasma transaminases (alanine aminotransferase, ALT and 
aspartate amino transferase, AST) were determined by method of 
Reitman and Frankel (1957). 

























Figure 1. Effect of artemether on serum alanine aminotransferase (ALT) activity. Different superscripts 
represent mean±S.D (n = 5) which is considered significant at p<0.05. Superscripts (a) and (b) compared with 




Construction of calibration curve was done by plotting the 
corresponding absorbance of standards against their respective 
AST/ALT activities. The measurable ranges with these graphs are 
from 5 to 150 U/L for ALT and 5 to 190 U/L for AST. 
Determination of plasma activity of alkaline phosphatase (ALP) in 
this study was done using spectrophotometric method as described 
elsewhere (Taiwo et al., 2003). The plasma activity of ALP was 
determined using this formula IU/L = 2760 × A of test in nm/min, 
where A is the absorbance at 405 nm and values of ALP were 
recorded for each sample. 
Plasma albumin level was determined by a method described 
elsewhere (Tijani et al., 2009). A calibration curve was prepared 
using various dilutions of the reagent albumin standard ranging 
from albumin concentrations of 0 to 50.0 g/L. Corresponding 
concentrations to various optical densities of all the samples 
analyzed were obtained using the prepared calibration curve and 





Results were tested using ANOVA and complemented with 
Student’s t-test and level of significance was set at P< 0.05. 
 
 
RESULTS AND DISCUSSION 
 
ALT and AST levels  significantly  increased  in  group  2, 
relative to the distilled water control group 1 ( P <0 .05) 
and non significantly lower in group 3, relative to group 2, 
and non significantly higher in group 4, relative to group 1 
(Figures 1 and 2). ALP mean levels slightly increased in 
group 2 as compared to group 1 and reasonably 
decreased, though insignificantly, in group 3, relative to 
group 2 (Figure 3). For ALB, there was an observed 
decrease in group 2, relative to group 1 and no difference 
in mean level between groups 1 and 4, and also between 
groups 2 and 3 (Figure 4). There was no significance 
difference in the mean body weights between weights 
taken before and after the experiment. 
The biochemical indices monitored in the liver were 
‘biomarkers’ for assessing hepatic damage and their 
activities in the blood played a significant role in the 
investigation and diagnosis (Dada and Omokhodion, 
2007) of effect on the liver cells and to a reasonable 
extent, the toxicity of the carbon tetrachloride (MacGregor 
and Lang, 1996) and the potential ameliorating effect of 
artemether.  
Furthermore, biochemical analysis of the carbon 
tetrachloride (CCl4) induced acute liver damage group 
revealed an observed increased but non-significant 
alkaline phosphatase level as compared to those of the 
distilled water control group  indicating a  possible assault

































Figure 2. Effect of artemether on serum aspartate aminotransferase (AST) activity. Different 
superscripts represent mean±S.D (n = 5) which is considered significant at p<0.05. 

























Figure 3. Effect of artemether on serum alkaline phosphatase (ALP) activity. Different 
superscripts represent mean±S.D (n = 5) which is considered significant at p<0.05. 
Superscripts (a) and (b) compared with CCl4, CCl4 + artemether and artemether, 
respectively. 




















Figure 4. Effect of artemether on serum albumin (ALB). Different superscripts represent mean±S.D (n 
= 5) which is considered significant at p<0.05. Superscripts (a) and (b) compared with CCl4, CCl4 + 




on the liver cells in line with the findings of Morakinyo et 
al. (2009). However, the non-significant change in the 
serum alkaline phosphatase activities (Figure 3) is an 
indication that there was no significant leakage of the 
enzyme into the serum. This suggests that CCl4 at the 
administered dose and period of time may be inducing 
the synthesis of the alkaline phosphatase in the tissues 
but possibly at a slow rate.  
Similarly, there was significant increase in enzyme 
activities of AST and ALT in CCl4 group, relative to the 
distilled water group. This may have resulted from 
increased functional activity of the tissues caused by CCl4 
in line with the findings of Hayes et al. (1986) indicating a 
possible hepatic injury. 
The observed reduction in albumin concentrations is a 
sign of liver damage, arising from the administration of 
the CCl4. This may be an indication of diminished 
synthetic function of the liver which may consequently 
lead to enhanced retention of fluid in the tissues spaces 
(Naganna, 1989). 
All these are in line with already documented toxic 
effect of CCl4 as a result of peroxidation of the membrane 
lipids by trichloromethyl radicals. These radicals initiate 
lipid peroxidation chain reactions that start with taking 
hydrogen ions from polyunsaturated fatty acids (PUFA). 
Peroxidation of lipids containing polyunsaturated fatty 
acids, in particular, impairs the structure of biological 
membranes, causing severe cell damage (Gasso et al., 
1996) which in this case is believed to be mild 
considering the low dosage and the short period of CCl4 
administration. 
However, the decrease in enzyme activities of the liver 
transaminases in CCl4
+
 artemether treated groups, 
relative to the CCl4 group is believed to have been due to 
a suspected free radical scavenger activity of artemether 
which is thought to be inhibitors of lipid peroxidation, and 
this confirms the findings of Xie et al. (2005). Decrease in 
the plasma alkaline phosphatase in the artemether 
treated groups may have been as a result of the inhibitory 
effect of the drug on the CCl4 induced synthesis of 
alkaline phosphatase within the hepatocells. This sug-
gests that artemether may have a possible repair effect 
on hepatocellular damage as it has a suspected inhibitory 
effect on CCl4 and may also enhance normal liver cell 
functions. There was no significant difference in the body 





Analysis of the result of this experimental study showed 





on hepato-cellular damage as it has a suspected 
inhibitory effect on CCl4 and may also enhance normal 
liver cell functions. 
During the course of this study, the major limiting factor 
was the time frame of the study, which did not allow for 
the long term study of the effect of the drug on the liver. 
Chronic carbon tetrachloride induced liver damage would 
have been more ideal for the study of hepatocellular 
repair and repair mechanism. Other constraints such as 
the inability to analyze more specific liver biomarkers is 
envisaged. 
The study of this novel antimalarial drug has also 
revealed other interesting prospects of artemether, 
especially in its possible regenerating activity. Further 
study to investigate specific enzyme makers, growth 
factors and mitogens, and their activity profiles is recom-
mended to provide further insight and understanding of 
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